trending Market Intelligence /marketintelligence/en/news-insights/trending/qMytLzPSmxLS83uRU5jEAQ2 content esgSubNav
In This List

Neos Therapeutics settles patent litigation against Actavis Laboratories

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Neos Therapeutics settles patent litigation against Actavis Laboratories

Neos Therapeutics Inc. granted Actavis Laboratories FL Inc. a license to market a generic version of its attention deficit hyperactivity disorder drug as part of a settlement agreement.

Neos had filed a patent litigation against the Teva Pharmaceutical Industries Ltd. unit after it sought U.S. Food and Drug Administration approval to introduce a generic version of Adzenys XR-ODT.

Under the settlement, Actavis Laboratories can market its generic drug starting Sept. 1, 2025, or earlier, under certain circumstances.

The agreement is subject to the approval of the Federal Trade Commission and the U.S. Department of Justice.